- Home
- PRZO vs PASG Comparison
PRZO vs PASG Comparison
Compare PRZO & PASG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PRZO | PASG |
|---|---|---|
| Founded | 2014 | 2017 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 25.1M | 28.6M |
| IPO Year | 2023 | 2020 |
Fundamental Metrics
Financial Performance| Metric | PRZO | PASG |
|---|---|---|
| Price | $1.26 | $12.42 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $34.50 |
| AVG Volume (30 Days) | ★ 2.7M | 89.2K |
| Earning Date | 08-28-2025 | 03-03-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,007,440.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 80.42 | N/A |
| 52 Week Low | $0.53 | $5.12 |
| 52 Week High | $2.15 | $20.00 |
Technical Indicators
Market Signals| Indicator | PRZO | PASG |
|---|---|---|
| Relative Strength Index (RSI) | 49.82 | 47.67 |
| Support Level | $1.15 | $11.81 |
| Resistance Level | $1.35 | $14.10 |
| Average True Range (ATR) | 0.15 | 2.37 |
| MACD | 0.01 | -0.61 |
| Stochastic Oscillator | 39.73 | 8.42 |
Price Performance
Historical ComparisonAbout PRZO ParaZero Technologies Ltd.
ParaZero Technologies Ltd is an aerospace company that is focused on drone safety systems and engaged in the business of designing, developing, and providing autonomous parachute safety systems for commercial drones, also known as unmanned aerial systems. The ParaZero SafeAir system of the company applies real-time data analytics to identify and mitigate flight risks autonomously and increase safety for bystanders while protecting the loss of expensive drones, equipment, and payloads.
About PASG Passage Bio Inc.
Passage Bio Inc is a genetic medicines company. The company is focused on developing transformative therapies for rare, monogenic CNS disorders. It has pipeline products such as GM1 Gangliosidosis, Frontotemporal dementia, and Krabbe Disease. The Company operates in a single reportable segment, developing and advancing genetic medicines designed to target critical underlying pathology of neurodegenerative diseases.